Replimune Group, Inc. (NASDAQ:REPL) Receives $9.75 Average PT from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $9.75.

REPL has been the topic of a number of research analyst reports. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, October 27th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research report on Monday, October 20th. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Replimune Group in a report on Monday, November 17th. Finally, Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $3.00 to $13.00 in a research report on Monday, October 20th.

Insider Buying and Selling

In other news, insider Konstantinos Xynos sold 7,248 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $65,956.80. Following the completion of the sale, the insider owned 139,685 shares in the company, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the transaction, the insider owned 123,088 shares in the company, valued at $1,120,100.80. The trade was a 4.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in Replimune Group by 8.4% during the 1st quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock worth $1,844,000 after buying an additional 14,659 shares during the period. Victory Capital Management Inc. lifted its position in shares of Replimune Group by 67.4% in the 1st quarter. Victory Capital Management Inc. now owns 75,140 shares of the company’s stock valued at $733,000 after acquiring an additional 30,260 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock worth $111,000 after purchasing an additional 5,876 shares during the period. US Bancorp DE boosted its stake in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after purchasing an additional 3,921 shares during the period. Finally, Vanguard Group Inc. grew its position in Replimune Group by 6.6% during the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock worth $37,372,000 after purchasing an additional 237,185 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $9.39 on Friday. The stock has a market cap of $736.55 million, a P/E ratio of -2.71 and a beta of 0.79. The firm’s 50-day simple moving average is $6.83 and its 200 day simple moving average is $7.41. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $15.12. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.